Compare Angi Inc (ANGI) vs 10X Genomics Inc (TXG) Price & Performance

ANGI trades at $4.41, down 3.92% with bearish technical signals and mixed fundamentals. Revenue declined to $1.03B in 2025, though net income improved to $44M. The stock appears undervalued with P/E of 14.81 and P/S of 0.19, but faces challenges with declining revenue trends and negative 2026 projections. Recent Q2 2026 earnings missed expectations with a $5.70 EPS loss versus $0.13 expected, while multiple law firms investigate potential securities violations.

Outlook remains challenging with revenue projected to decline to $993M in 2026 and net loss of $222M. The 59% upside to consensus price target of $7.00 offers potential reward, but risks include accelerating pro user churn, negative cash flow trends, and ongoing securities investigations. Analyst sentiment is cautious with 64% hold ratings amid fundamental deterioration.

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.